17.4.2026 07:00:02 CEST | Thor Medical ASA | Non-regulatory press releases

Thor Medical, a leading emerging supplier of alpha-emitters for next-generation
precision cancer treatment, today announced that its AlphaOne production
facility at Herøya Industrial Park has reached mechanical completion. The plant
is now fully constructed, on time and budget, and progressing as planned toward
production start in the third quarter this year.

"This is a major achievement for Thor Medical and a testament to the strong
execution capabilities of our team and partners," said Jasper Kurth, Chief
Executive Officer of Thor Medical ASA.

Mechanical completion confirms that all major construction and installation
activities have been finalized in accordance with project specifications. The
facility has now entered the commissioning phase, which partly commenced already
in March. During commissioning, systems and equipment are being tested,
verified, and prepared for operational start-up. Commissioning activities are
expected to continue toward production start in the third quarter this year.

"Reaching Mechanical Completion, alongside the successful start of
commissioning, keeps us firmly on track toward commencing production in the
third quarter and delivering on our strategy to become a leading supplier of
alpha-emitting radioisotopes for cancer treatment," Kurth added.

The AlphaOne facility at Herøya Industrial Park will play a central role in Thor
Medical's mission to address the growing global demand for radiopharmaceuticals.

CONTACTS

 * Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, +47 988
   05 724, mathias.reierth@thormedical.com 

ABOUT THOR MEDICAL ASA

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of alpha particle emitters produced from
naturally occurring thorium, a key component of next-generation targeted cancer
treatment. Its proprietary production process requires no irradiation or use of
nuclear reactors, and provides a reliable, environmentally friendly and
cost-efficient supply of alpha emitters to the radiopharmaceutical industry.
Guided by its vision to become a world-leading enabler for targeted cancer
therapies, Thor Medical is committed to improving millions of lives by fueling
next-generation cancer therapies with high-purity isotopes. Thor Medical is
headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the
ticker symbol TRMED. For more information, visit www.thormedical.com -
http://www.thormedical.com - https://www.thormedical.com.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18866090/7526/Download%20announce
ment%20as%20PDF.pdf